Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA

View/Open
Date
2017
Author
Bozkurt, Murat Fani
Virgolini, Irene
Balogova, Sona
Beheshti, Mohsen
Rubello, Domenico
Decristoforo, Clemens
Ambrosini, Valentina
Kjaer, Andreas
Delgado-Bolton, Roberto
Kunikowska, Jolanta
Oyen, Wim J. G.
Chiti, Arturo
Giammarile, Francesco
Fanti, Stefano
xmlui.mirage2.itemSummaryView.MetaData
Show full item record
Abstract
Purpose & Methods Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using Ga-68-DOTA-conjugated peptides, as well as F-18-DOPA imaging for various neuroendocrine neoplasms. Results & Conclusion The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with Ga-68-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
URI
https://doi.org/10.1007/s00259-017-3728-y
http://hdl.handle.net/11655/15778
xmlui.mirage2.itemSummaryView.Collections